Testing effectiveness (Phase 2)UnknownNCT04994626
What this trial is testing
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
Who this might be right for
DLBCLMYD88 Gene MutationCD79A Gene Mutation+3 more
Chinese Academy of Medical Sciences 20